NovaBay Pharmaceuticals, Inc. (NYSE:NBY) rose sharply Tuesday after rising around 875% Monday after the company reached an agreement to sell its eye care product on Amazon.com.
The Emeryville, Calif-based NovaBay, a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that Avenova® Direct is available at affordable pricing and without a prescription on Amazon through the Company’s new direct-to-consumer online channel.
Avenova, the leading lid and lash spray, is designed for the removal of bacteria and debris on and around the eyelid margin that contribute to bacterial eye infections, which represent approximately 85% of the dry eye market.
Avenova Direct is available from Amazon in the U.S. in a 20ml size for $29.99. Avenova is gentle, refreshing and soothing for everyday eyelid and eyelash use.
The launch of NovaBay’s direct-to-consumer channel is supported by Avenova’s existing brand awareness campaign.
In addition, the Company is conducting a comprehensive online promotional strategy that includes search engine optimization, Google Ads and Amazon promotions using searchable keywords, Facebook lead ads and social media marketing targeting influencers, and email campaigns focused on ophthalmologists, optometrists and current and former Avenova patients.
Said CEO Justin Hall, "Patients throughout the U.S. can now purchase Avenova Direct without a prescription in Avenova’s original prescription formulation.
"For many years, the bacterial microorganisms that are the underlying cause of the vast majority of dry eye cases were almost impossible to manage. Avenova Direct effectively manages bacterial dry eye through our pure 0.1% hypochlorous acid formulation in saline, which is free from bleach, surfactants and other impurities."
Shares gathered 61 cents, or 19.7%, to $3.74
